Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Franklin D. Gaylis, MD Inc. |
---|---|
Information provided by: | Franklin D. Gaylis, MD Inc. |
ClinicalTrials.gov Identifier: | NCT00680680 |
To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will alleviate urinary retention secondary to BPH in who have failed a voiding trial without a catheter. Following treatment with an Alpha Blocker alone.
Condition | Intervention |
---|---|
Urinary Retention Benign Prostatic Hyperplasia |
Drug: Dutasteride |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | Phase 4 Study of Dual Five Alpha Reductase Inhibition Combined With Alpha Blockade in Men With Refractory Urinary Retention Secondary to BPH |
Estimated Enrollment: | 20 |
Study Start Date: | May 2004 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 50 Years to 90 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | MEDRESEARCH ( Franklin D. Gaylis, M.D. ) |
Study ID Numbers: | AUR |
Study First Received: | May 16, 2008 |
Last Updated: | May 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00680680 |
Health Authority: | United States: Institutional Review Board |
Urinary retention secondary to benign prostatic hyperplasia |
Dutasteride Hyperplasia Prostatic Diseases Urologic Diseases Prostatic Hyperplasia |
Urination Disorders Neoplasm Metastasis Genital Diseases, Male Urinary Retention |
Pathologic Processes Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Pharmacologic Actions |